SeaStar Medical: Pediatric Momentum Meets a 2.3-Quarter Cash Runway

QUELIMMUNE grows 82% and the adult AKI trial tracks to submission, but a razor-thin balance sheet makes the next raise the real pivot.

ICU · Earnings Call · 2026-08-12

A small but growing beachhead

SeaStar Medical’s second-quarter 2026 report is a study in contrasts: commercial momentum in the ultra-rare at extreme cost pressure. The company recorded $615,000 of net revenue for the quarter, an 82% jump from the prior year’s $338,000, driven by adult AKI expectations and growing use of QUELIMMUNE therapy in pediatric critical care. On the call, CEO Eric Schlorff framed the thesis plainly: “Our pediatric AKI market penetration and continued strong QUELIMMUNE revenue growth bodes well for our future potential opportunity in the adult AKI market, that is 50x larger than the pediatric market in The United States.” — Eric Schlorff, Chief Executive Officer · 2026-08-12 The commercial team has already doubled its hospital base this year, reaching 20 of the 50 premier children’s hospitals in the U.S., and Tim Varacek added that “we are well on our way to achieving that goal” — Tim Varacek, Senior Vice President of Commercial and Business Operations · 2026-08-12 of 25 by year-end. That expansion is not just about patient numbers; the company is seeing high repurchase rates from existing sites, a pattern that was already visible in the May call when Varacek told analysts, “We absolutely see repeat orders from our customer base.” — Tim Varacek, Vice President of Sales · 2026-05-13 Still, the revenue base remains tiny, and the company is burning cash at a pace that makes the runway the real story.

Trial enrollment and the adult AKI opportunity

The most consequential update concerns the NEUTRALIZE-AKI pivotal trial for adult patients. Management reiterated the target of completing enrollment by year-end 2026 or early 2027, with a modular PMA submission by end-2027. The clinical team is maintaining a careful balance between speed and trial integrity. Chief Medical Officer Colonel Kevin Chung emphasized that

we have to get the right patients. what is the point in getting finished with enrollment if we enroll a bunch of patients out of haste to try to just get our number and we are not enrolling the right patients.
Colonel Kevin Chung FACP · 2026-08-12

On the enrollment rate, he noted that the study has been adding “somewhere around 8 to 10 to 12 patients in each of those months” — Colonel Kevin Chung FACP · 2026-08-12, which is slower than desired but still points to a year-end finish if new high-volume sites come online as planned. The company’s keyword trajectory reinforces the shift: “adult AKI” and “New sites” have been the top two themes in recent quarters, and the same concepts dominate the New sites and ARDS bucket discussion on the call. Earlier this year, the company was already planning to expand the trial to 25 sites, with Kevin Chung noting in November 2025 that “We are currently at 146 patients enrolled. We have 17 sites activated.” — Kevin Chung, Chief Medical Officer · 2025-11-13 The current enrollment pace suggests the trial is tracking toward that December 2026 goal, but the company has not yet disclosed updated enrollment numbers, leaving investors to interpolate from monthly anecdotes.

The cash runway question

What really stands out is the balance sheet. Effective net cash stood at $7.0 million at quarter-end, and operating losses remain around $4 million per quarter. The company’s cash runway per the fundamentals is 2.3 quarters — a figure that has bounced around but is now near the lower end of its history. R&D spending jumped 143% year-over-year to $3 million, accelerating as the trial ramps, while operating income deteriorated further to -$4 million. Even as revenue grows, the burn is widening, and the company will likely need to tap the capital markets before the year is out. The company has not announced a financing plan, but with a market cap of just $15.9 million, any dilution would be substantial. The stock has already been punished, down 26.4% over the last 90 days to $3.15, still far below its 2022 peak of over $3,000. The drawdown from the recent peak of $5.08 is -39.2%. That price action suggests the market is pricing in a high probability of dilution or failure.

What to watch

The next few quarters will be binary for SeaStar. If NEUTRALIZE-AKI enrolls on schedule and hits its primary endpoint, the adult AKI market — 50x the size of the pediatric one — becomes a tangible opportunity. But the company must also secure financing to get there. The management team’s focus on NEUTRALIZE AKI and the pediatric critical care community is clear, but the cash runway is the ultimate gating factor. Investors should watch for (1) monthly enrollment updates, (2) any new site activations, and (3) any financing announcement. The company’s own adult AKI narrative is compelling, but it is now a race against the clock.